Entinostat (MS-275, SNDX-275): Epigenetic Modulation in Cancer and Regeneration Research

Introduction

Recent advances in the field of epigenetics have revolutionized our understanding of gene regulation and disease progression. Central to this revolution is the study of histone deacetylases (HDACs), key enzymes that modulate chromatin structure, thereby influencing gene expression patterns pivotal to oncogenesis and tissue regeneration. Entinostat (MS-275, SNDX-275), a potent, orally available HDAC1 and HDAC3 inhibitor, has emerged as a cornerstone molecule for both cancer research and, as revealed by recent studies, regenerative biology. This article provides a comprehensive exploration of Entinostat, focusing on its unique mechanisms, translational oncology applications, and novel insights into its role in tissue repair and regeneration—delivering a perspective distinct from existing discussions of its anticancer utility.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

HDAC Inhibition and Epigenetic Regulation

HDACs are pivotal in regulating the acetylation status of histones, thereby impacting chromatin compaction and gene transcription. Class I HDACs, particularly HDAC1, HDAC3, and HDAC8, are integral to silencing tumor suppressor genes and maintaining oncogenic phenotypes. Entinostat, also known as MS-275 or SNDX-275, is a highly selective oral HDAC inhibitor, exhibiting IC₅₀ values of 0.368 μM (HDAC1), 0.501 μM (HDAC3), and 63.4 μM (HDAC8). This selectivity underpins its efficacy and safety profile, distinguishing it from broader-spectrum HDAC inhibitors that often elicit off-target effects.

Upon administration, Entinostat binds to the catalytic domain of HDAC1 and HDAC3, blocking their deacetylase activity. This leads to the accumulation of acetylated histones, resulting in chromatin relaxation and reactivation of silenced genes, including key tumor suppressors. Downstream effects include the inhibition of cancer cell proliferation, induction of apoptosis (via caspase-3/7 activation and G1 cell cycle arrest), and modulation of the tumor microenvironment. Furthermore, Entinostat enhances acetyl-histone levels in target tissues, as demonstrated in both in vitro and in vivo cancer models.

Solubility, Stability, and Laboratory Use

Entinostat is insoluble in water but dissolves readily in DMSO (≥18.8 mg/mL) and ethanol (≥7.4 mg/mL with ultrasonic assistance). For optimal solubility, warming to 37°C and ultrasonic shaking are recommended. Stock solutions are stable for several months at -20°C, but long-term storage in solution is not advised. These characteristics make Entinostat ideal for experimental workflows requiring consistent, high-concentration dosing and reproducible results.

Beyond Oncology: Entinostat in Regenerative Biology

Lessons from Limb Regeneration: HDAC1 in Axolotls

While the anti-cancer properties of Entinostat are well recognized, recent research has illuminated its impact on tissue regeneration. In a seminal study published in Developmental Biology (Wang et al., 2019), Entinostat (MS-275) was used to probe the role of HDAC1 in axolotl limb regeneration. The study revealed a bi-phasic upregulation of HDAC1 expression during blastema formation—an essential process for successful limb regeneration. Pharmacological inhibition of HDAC1 using Entinostat led to pronounced delays in blastema formation and limb regrowth, establishing a direct link between HDAC1 activity and regenerative capacity. Notably, this effect was specific to the regeneration phase and did not impair initial wound healing.

These findings provide a unique perspective on the dual role of HDAC1—as both a target for cancer therapy and a regulator of regenerative processes. The study also highlights the complex interplay between nerve signaling, wound epidermis, and HDAC1-mediated epigenetic modulation, offering new avenues for research at the intersection of oncology and regenerative medicine.

Implications for Mammalian Tissue Repair

Although axolotls possess remarkable regenerative capabilities absent in adult mammals, the molecular pathways uncovered—including HDAC1 signaling—are evolutionarily conserved. The ability of Entinostat to modulate these pathways raises intriguing possibilities for its use in promoting or controlling regenerative processes in mammalian models, such as retinal tissue repair or attenuation of fibrosis. Such applications remain underexplored in the current literature and represent a promising frontier for translational research.

Translational Oncology: Entinostat in Cancer Research and Clinical Trials

Anti-Proliferative and Pro-Apoptotic Effects

Entinostat has demonstrated broad-spectrum anti-tumor activity across a range of human cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia. Its cytotoxic effects are mediated by increased reactive oxygen species, activation of intrinsic apoptosis pathways, and induction of G1 cell cycle arrest. Importantly, systemic administration in vivo has been shown to significantly reduce tumor burden and elevate acetyl-histone levels in tissues, such as the retina in murine and rat models of retinoblastoma.

Solid Tumor Clinical Trials

Clinical trials have evaluated Entinostat in combination with agents like 13-cis retinoic acid (CRA), demonstrating tolerable safety profiles and establishing recommended phase II dosing regimens. These trials underscore the compound's translational potential as both a monotherapy and an adjunct to existing chemotherapeutic or targeted regimens. The specificity for HDAC1 and HDAC3 may confer a favorable balance between efficacy and toxicity, especially compared to less selective HDAC inhibitors.

Regulation of Tumor Suppressor Genes and the HDAC Signaling Pathway

By reversing epigenetic silencing of tumor suppressor genes, Entinostat disrupts critical survival pathways in malignant cells. This reprogramming effect is central to its role in cancer therapy, positioning Entinostat as a paradigm of epigenetic modulation in oncology. For a detailed discussion on mechanistic intricacies and translational applications, readers may consult this article on mechanistic insights and translational oncology; however, the current review uniquely expands the scope to include regenerative biology and comparative frameworks between cancer and tissue repair.

Comparative Analysis: Entinostat Versus Broader HDAC Inhibitors

Most existing content, such as precision epigenetic modulation in cancer, focuses on Entinostat's selectivity and apoptotic effects in tumor suppressor gene regulation. While these are crucial facets, this article adopts a broader viewpoint, critically examining Entinostat's unique pharmacological profile and its emerging relevance in non-oncological contexts. Unlike pan-HDAC inhibitors, which may compromise normal tissue function and elicit severe toxicity, Entinostat's class I selectivity (HDAC1/3) provides a targeted approach that minimizes collateral effects, thus making it an attractive candidate for both cancer research and, potentially, regenerative medicine.

Furthermore, while other resources (e.g., advancing cancer research via epigenetic modulation) emphasize in vitro analytics and workflow integration, the present discussion integrates comparative insights from developmental biology, thereby bridging in vitro, in vivo, and cross-species applications—a perspective underrepresented in existing literature.

Advanced Applications and Future Directions

Retinoblastoma and Beyond: The Promise of HDAC Inhibition

Preclinical studies have established that Entinostat reduces tumor burden in models of retinoblastoma by increasing acetyl-histone levels in retinal tissue. This not only positions Entinostat as a promising candidate for retinoblastoma treatment research but also suggests potential roles in other ocular or CNS malignancies where epigenetic dysregulation drives pathology. The ability to modulate the histone deacetylase signaling pathway opens avenues for combination therapies and personalized oncology strategies.

Epigenetic Modulation in Regenerative Medicine

Building on the findings from axolotl limb regeneration, future research may exploit HDAC inhibitors like Entinostat to fine-tune tissue repair and regeneration in mammals. By targeting HDAC1 and HDAC3, it may be possible to promote beneficial gene expression signatures during wound healing or to modulate scarring and fibrosis. Such applications, while nascent, underscore the need for interdisciplinary studies at the interface of cancer research and regenerative biology.

Practical Considerations for Researchers

Entinostat is conveniently supplied as a solid by APExBIO and is shipped on blue ice to ensure stability. Researchers are advised to adhere to recommended storage (-20°C) and solubilization protocols to maintain compound integrity. The product’s robust stability in DMSO and ethanol facilitates its integration into a range of experimental designs, from high-throughput screening to in vivo modeling.

Conclusion and Future Outlook

Entinostat (MS-275, SNDX-275) stands at the forefront of epigenetic research, offering unparalleled selectivity as an oral HDAC1 and HDAC3 inhibitor. Its dual impact—potently inhibiting cancer cell proliferation and apoptosis, while also modulating regenerative processes via HDAC1—positions it as a unique tool for both oncology and tissue engineering studies. While previous literature has focused on its anticancer mechanisms and translational oncology (see comparative oncology research), this article underscores the broader biological and translational implications of targeted HDAC inhibition.

As research continues to unravel the complexities of epigenetic regulation, Entinostat—available from APExBIO—will remain indispensable for probing the molecular underpinnings of both disease and regeneration. Future directions should prioritize interdisciplinary collaborations to fully realize the therapeutic and regenerative potential of selective HDAC inhibition.